avail
rapid
reliabl
viral
diagnost
test
particularli
nucleic
acid
amplif
test
naat
facilit
decis
make
prevent
treatment
public
health
infect
control
measur
relat
viral
infect
specif
antivir
therapi
avail
mani
clinic
relev
virus
specif
viral
diagnosi
may
limit
need
diagnost
test
unnecessari
antibiot
therapi
two
major
approach
diagnosi
viral
infect
virolog
detect
viru
serolog
detect
antibodi
antigen
virolog
approach
includ
isol
infecti
viru
cell
cultur
detect
viral
antigen
immunolog
method
eg
fluoresc
antibodi
fa
test
enzym
immunoassay
eia
visual
viral
particl
electron
microscopi
em
detect
viral
nucleic
acid
molecular
techniqu
eg
hybrid
naat
cytolog
examin
tissu
cell
may
identifi
viral
effect
thu
prompt
investig
occasion
cytolog
chang
suffici
specif
suggest
particular
agent
eg
cytomegaloviru
cmv
serolog
approach
includ
detect
follow
virusspecif
antibodi
indic
recent
current
past
infect
well
immun
follow
recoveri
vaccin
signific
rise
virusspecif
immunoglobulin
g
igg
antibodi
suggest
acut
recent
infect
virusspecif
antigen
eg
hepat
b
surfac
antigen
hbsag
virusspecif
igm
antibodi
late
acut
earli
recoveri
phase
sera
immun
respons
matur
follow
viral
infect
lowavid
igg
antibodi
replac
highavid
antibodi
eia
capabl
measur
avid
igg
antibodi
specif
virus
use
distinguish
primari
secondari
reactiv
antibodi
respons
vaccin
natur
infect
clinic
laboratori
test
detect
viru
infect
divid
specif
categori
use
make
specif
diagnosi
measur
viru
activ
patient
known
infect
eg
viral
load
test
human
immunodefici
viru
hiv
screen
infect
carrier
state
eg
transplant
blood
donat
detect
virus
specimen
collect
soon
onset
clinic
symptom
prefer
within
first
day
viral
shed
greatest
prefer
optim
specimen
vari
depend
site
site
diseas
gener
tissu
aspir
bodi
fluid
superior
swab
bodi
site
lesion
sampl
easili
swab
includ
pharynx
nasopharynx
conjunctiva
urethra
cervix
vagina
vesicl
ulcer
skin
mucou
membran
mani
swab
type
avail
specimen
collect
includ
plastic
swab
wooden
swab
swab
flexibl
wire
shaft
tip
made
cotton
dacron
calcium
algin
polyurethan
although
suitabl
detect
virus
swab
wooden
shaft
contain
toxic
product
inactiv
herp
simplex
viru
hsv
cottontip
swab
contain
fatti
acid
interfer
surviv
chlamydia
speci
suitabl
collect
specimen
vagina
cervix
urethra
detect
mycoplasma
calcium
alginatetip
swab
toxic
lipidenvelop
virus
herpesvirus
cell
cultur
use
collect
specimen
chlamydia
although
swab
place
viral
transport
medium
vtm
use
naat
mani
commerci
assay
detect
virus
chlamydia
provid
swab
transport
media
use
virus
caus
morpholog
chang
ie
cytopath
effect
cpe
cell
monolay
virus
caus
cpe
within
day
eg
hsv
other
within
week
eg
enterovirus
other
sever
week
eg
cmv
virus
caus
typic
cpe
detect
base
adsorpt
red
blood
cell
surfac
virusinfect
cell
cultur
eg
influenza
parainfluenza
virus
use
interfer
assay
eg
rubella
viru
presumpt
identif
particular
viru
viru
group
cell
cultur
base
cell
type
time
appear
cpe
sourc
specimen
suspect
clinic
diagnosi
confirm
viru
isol
requir
immunolog
method
fluoresceinor
peroxidaseconjug
virusspecif
monoclon
polyclon
antibodi
antibodi
hsv
cmv
vzv
rsv
influenza
b
viru
parainfluenza
viru
adenoviru
measl
viru
enteroviru
antigen
readili
avail
centrifug
specimen
refer
shell
vial
spinamplifi
cultur
onto
cell
monolay
coverslip
place
bottom
small
vial
well
follow
incub
stain
viral
antigen
use
monoclon
antibodi
day
shorten
time
requir
detect
confirm
presenc
mani
virus
replac
convent
cultur
mani
laboratori
slowli
grow
virus
cmv
use
monoclon
antibodi
nonstructur
protein
produc
earli
replic
cycl
ie
immedi
earli
antigen
ea
ea
allow
detect
viru
day
week
cpe
observ
tradit
cell
cultur
techniqu
two
techniqu
isol
virus
develop
sensit
compar
standard
cultur
shell
vial
method
genet
engin
cell
line
enzymelink
virusinduc
system
elvi
quidel
san
diego
calif
use
babi
hamster
kidney
cell
line
transform
use
hsvinduc
promot
gene
escherichia
coli
gene
introduc
isol
hsv
addit
substrat
enzym
result
format
color
reaction
hsvinfect
cell
techniqu
adapt
perform
rapid
hsv
antivir
suscept
test
mix
multipl
cell
type
singl
shell
vial
cultur
provid
rapid
detect
follow
respiratori
virus
rmix
quidel
hsv
cmv
vzv
h
vmix
quidel
enterovirus
emix
quidel
viru
antigen
detect
test
perform
directli
varieti
specimen
type
highli
specif
rapid
viru
antigen
cell
associ
collect
adequ
number
infect
cell
import
sever
commerci
kit
eia
latex
agglutin
fa
avail
detect
follow
rotaviru
enter
adenoviru
stool
specimen
rsv
influenza
b
virus
parainfluenza
virus
adenovirus
respiratori
tract
specimen
hbsag
hiv
antigen
serum
hsv
vzv
vesicl
ulcer
swab
specimen
cmv
bal
blood
specimen
fa
techniqu
use
detect
rabi
viru
brain
tissu
mump
viru
throat
urin
sediment
measl
viru
conjunctiv
cell
detect
cmv
antigen
neutrophil
use
diagnosi
manag
new
reactiv
cmv
infect
immunocompromis
patient
although
almost
specimen
type
suitabl
em
laboratori
replac
em
viru
detect
method
laboratori
continu
use
em
detect
gastrointestin
pathogen
rotaviru
enter
adenovirus
noroviru
well
detect
bkpolyomaviru
tissu
biopsi
urin
sampl
disadvantag
em
includ
larg
number
viru
particl
approxim
ml
specimen
requir
detect
limit
throughput
expens
lack
avail
expertis
mani
center
increas
sensit
avail
naat
detect
almost
clinic
relev
viru
revolution
test
swab
tissu
detect
virus
place
vtm
prevent
dri
maintain
viru
viabil
prevent
overgrowth
contamin
organ
sever
commerci
prepar
vtm
avail
swab
collect
bacteri
isol
place
bacteri
transport
medium
unaccept
detect
virus
convers
vtm
contain
antimicrobi
agent
inhibit
bacteria
fungi
specimen
blood
bone
marrow
cerebrospin
fluid
csf
urin
bodi
fluid
place
clean
steril
contain
without
vtm
detect
respiratori
virus
nasopharyng
np
aspir
wash
sputum
bronchoalveolar
lavag
bal
specimen
provid
better
yield
detect
virus
np
nasal
throat
swab
multipl
sampl
requir
maxim
yield
freshli
pass
stool
superior
rectal
swab
detect
gastrointestin
virus
specif
virus
found
differ
blood
cell
plasma
serum
eg
hiv
lymphocyt
macrophag
cmv
neutrophil
lesser
extent
mononuclear
cell
enterovirus
plasma
white
blood
cell
blood
collect
vacutain
tube
contain
anticoagul
ethylenediaminetetraacet
acid
edta
recoveri
rate
higher
edta
heparin
heparin
inactiv
herpesvirus
inhibit
naat
issu
may
less
concern
realtim
polymeras
chain
reaction
pcr
relat
type
heparin
sodium
vs
lithium
use
tissu
specimen
labil
particular
virus
eg
respiratori
syncyti
viru
rsv
varicellazost
viru
vzv
concern
vtm
contain
albumin
serum
stabil
use
virus
stabl
day
refriger
wet
ice
temperatur
freez
ordinari
freezer
temperatur
destroy
reduc
infect
virus
alter
abil
detect
viral
antigen
use
commerci
avail
kit
beyond
day
specimen
store
ultralowtemperatur
freezer
transport
dri
ice
naat
eg
detect
hepat
c
viru
hcv
rna
serum
plasma
serum
plasma
separ
within
hour
collect
process
within
hour
kept
frozen
test
serolog
detect
viral
antibodi
antigen
blood
transport
room
temperatur
delay
anticip
specimen
kept
refriger
serum
plasma
separ
soon
possibl
specimen
collect
extend
period
elaps
test
serum
plasma
sampl
frozen
lower
repeat
freezethaw
cycl
avoid
virus
igm
assay
avail
eg
hepat
viru
hav
acut
phase
specimen
suffici
diagnosi
otherwis
acut
phase
specimen
collect
within
day
ill
onset
serum
store
follow
collect
convalesc
phase
specimen
week
later
specimen
test
simultan
laboratori
perform
viru
isol
use
monolay
cell
cultur
techniqu
howev
mani
clinic
relev
virus
parvoviru
human
papillomaviru
hepat
virus
epsteinbarr
viru
ebv
rotavirus
norovirus
other
cultivat
routin
diagnost
laboratori
laboratori
diagnosi
base
method
although
cultiv
hiv
possibl
use
suspens
cultur
lymphocyt
special
contain
facil
requir
altern
method
use
routin
diagnosi
major
virus
detect
isol
monolay
cell
cultur
includ
cmv
vzv
rsv
influenza
b
virus
parainfluenza
virus
respiratori
adenovirus
sever
enterovirus
coxsackieviru
echoviru
polioviru
measl
viru
cultivat
virus
replic
singl
cell
line
thu
variou
cell
line
use
primari
isol
diploid
cell
line
human
foreskin
lung
fibroblast
herpesvirus
primari
cell
line
primari
rhesu
monkey
kidney
cell
respiratori
virus
enterovirus
heteroploid
continu
human
epitheli
cell
line
cell
rsv
type
cell
line
use
diagnost
laboratori
determin
specimen
type
season
epidemiolog
data
clinic
inform
provid
mani
part
iv
laboratori
diagnosi
therapi
infecti
diseas
competit
assay
result
usual
measur
optic
densiti
od
unit
color
reaction
result
report
either
qualit
quantit
intern
unit
iu
index
valu
interpret
optic
densiti
unit
vari
eiaelisa
kit
use
viru
antibodi
detect
rel
newer
modif
eia
known
chemiluminesc
immunoassay
use
enzym
substrat
combin
gener
light
signal
result
report
rel
light
unit
rlu
chemiluminesc
immunoassay
gener
consid
sensit
eia
presenc
virusspecif
igm
antibodi
serum
obtain
week
onset
ill
permit
diagnosi
acut
recent
infect
mani
virus
typic
igm
antibodi
disappear
serum
within
month
acut
ill
persist
extend
time
peopl
virus
falseposit
igm
result
caus
crossreact
eg
among
herpesvirus
polyclon
stimul
secondari
ebv
infect
presenc
rheumatoid
factor
igm
antibodi
bind
fc
portion
igg
inher
test
difficulti
misinterpret
igm
antibodi
indic
acut
recent
infect
also
occur
result
persist
igm
antibodi
sever
month
acut
ill
eg
ebv
west
nile
viru
reactiv
latent
chronic
virus
eg
hsv
hbv
falseneg
igm
test
result
reflect
follow
absent
low
delay
igm
respons
especi
immunolog
immatur
host
eg
infanc
congenit
cmv
hiv
infect
immunosuppress
patient
eg
patient
acquir
immunodefici
syndrom
aid
presenc
hightit
igg
antibodi
preclud
bind
igm
mani
commerci
avail
kit
contain
reagent
adsorb
igg
test
serum
use
background
subtract
step
thu
reduc
possibl
interfer
igg
antibodi
test
use
determin
suscept
immun
particular
viru
sensit
method
import
detect
neutral
antibodi
best
predictor
immun
major
advantag
serolog
diagnosi
acut
viral
infect
includ
noncrit
specimen
handl
wide
avail
disadvantag
includ
requir
acut
convalesc
sera
igg
antibodi
test
falseposit
falseneg
igm
antibodi
result
delay
week
diagnosi
confirm
shortincub
infect
mani
confound
factor
eg
passiv
transfer
antibodi
mother
infant
receipt
immunoglobulin
immunocompromis
serolog
test
result
alway
interpret
within
context
clinic
situat
whenev
possibl
serolog
diagnosi
confirm
use
viru
isol
direct
detect
viru
antigen
nucleic
acid
depend
serolog
assay
either
serum
plasma
use
use
specimen
type
well
valid
clinic
virolog
laboratori
mani
laboratori
naat
supplant
viru
cultur
antigen
detect
method
direct
molecular
hybrid
techniqu
three
approach
taken
target
amplif
pcr
strand
displac
amplif
nucleic
acid
sequencebas
amplif
transcriptionmedi
amplif
system
probe
amplif
includ
replicas
ligas
chain
reaction
signal
amplif
branchedchain
dna
bdna
assay
hybrid
captur
assay
sever
commerci
inhous
homebrew
assay
develop
quantif
viral
genom
plasma
serum
use
determin
prognosi
select
patient
antivir
therapi
monitor
respons
treatment
varieti
patient
popul
multiplex
assay
capabl
detect
sever
virus
singl
amplif
reaction
develop
eg
herpesvirus
enter
bloodborn
respiratori
virus
studi
suggest
assay
costeffect
develop
autom
realtim
pcr
use
fluoresc
techniqu
continu
detect
amplifi
product
shorten
detect
time
substanti
rel
convent
pcr
assay
assay
use
close
system
ie
amplif
detect
occur
singl
tube
need
open
reaction
complet
also
less
prone
contamin
convent
pcr
naat
appli
genotyp
virus
eg
hiv
hbv
hcv
well
detect
mutat
confer
resist
antivir
agent
newer
molecular
techniqu
pyrosequenc
wholegenom
sequenc
begin
appli
clinic
laboratori
provid
improv
genotyp
virus
detect
viru
quasispeci
metagenom
analysi
detect
exist
new
novel
virus
clinic
specimen
choos
optim
test
depend
specif
viru
sought
clinic
set
specimen
type
avail
kit
reagent
equip
experi
laboratori
personnel
cost
use
naat
rapidli
replac
older
viral
diagnost
method
rapid
turnaround
time
superior
sensit
abil
quantifi
viru
densiti
naat
sever
rel
simpl
inhous
commerci
avail
naat
avail
wide
varieti
virus
howev
laboratori
continu
use
antigen
detect
method
viru
cultur
expertis
molecular
techniqu
avail
cost
prohibit
serolog
method
use
diagnos
current
recent
acut
infect
determin
specif
suscept
immun
epidemiolog
surveil
purpos
interpret
serolog
result
viru
specif
exampl
presenc
hiv
antibodi
indic
current
infect
wherea
presenc
igg
antirubella
indic
immun
result
immun
recoveri
natur
infect
serolog
diagnosi
acut
infect
use
incub
period
prolong
eg
week
antibodi
present
serum
concomitantli
sign
ill
eg
ebv
cmv
mononucleosi
fig
show
typic
antibodi
respons
acut
moderateincub
sever
day
week
viral
ill
measl
onset
rash
manifest
antibodi
undetect
present
low
titer
within
day
appreci
titer
antibodi
present
shortincub
viru
infect
eg
respiratori
virus
rise
antibodi
usual
occur
late
recoveri
phase
convalesc
therefor
valu
diagnosi
acut
infect
older
serolog
method
hemagglutin
inhibit
complement
fixat
cf
reli
greater
fourfold
rise
antibodi
titer
acut
convalesc
sera
test
parallel
larg
replac
solid
phase
immunoassay
eia
passiv
latex
agglutin
immunofluores
assay
ifa
presenc
antibodi
high
titer
singl
serum
specimen
convalesc
usual
permit
definit
diagnosi
seroconvers
use
diagnos
acut
recent
infect
eia
elisa
highli
standard
quantit
detect
igg
igm
antibodi
virus
hiv
hcv
simultan
detect
antigen
antibodi
singl
assay
eia
noncompetit
sandwich
assay
virus
assay
except
includ
use
saliva
detect
hiv
antibodi
csf
patient
viral
central
nervou
system
cn
diseas
optim
test
specif
virus
tabl
contain
list
medic
import
virus
major
attribut
diseas
optim
diagnost
specimen
avail
test
averag
time
posit
test
result
mani
test
time
obtain
result
function
test
eg
cultur
logist
laboratori
test
schedul
need
refer
sampl
refer
laboratori
prefer
test
provid
fastest
result
accept
sensit
specif
prefer
diagnost
test
test
vari
depend
patient
popul
test
eg
immunocompromis
host
clinic
indic
optim
test
diagnosi
member
herpesvirida
famili
vari
viru
type
suspect
mucocutan
lesion
caus
hsv
vzv
clinic
diagnosi
usual
suffici
laboratori
confirm
requir
aspir
swab
vesicular
fluid
scrape
ulcer
base
place
vtm
recommend
potenti
use
sampl
includ
blood
edta
viremia
suspect
averag
time
posit
result
may
much
function
test
eg
cultur
frequenc
test
perform
laboratori
c
prefer
test
basi
sensit
specif
short
time
posit
test
result
acut
convalesc
week
onset
ill
serolog
test
recommend
virus
igm
antibodi
test
avail
cmv
ebv
hav
hbvcore
hsv
measl
mump
parvoviru
rubella
varicellazost
viru
e
case
sexual
abus
rape
cultur
recommend
concern
falseposit
result
noncultur
method
f
pcr
test
time
posit
result
vari
eg
neonat
csf
steril
contain
mening
enceph
suspect
conjunctiv
swab
corneal
scrape
vtm
suspect
case
herp
kerat
tissu
biopsi
vtm
frozen
eg
dissemin
hsv
vzv
neonat
immunocompromis
patient
infant
duoden
aspir
also
collect
suspect
neonat
hsv
infect
test
isol
viru
direct
detect
viral
antigen
cell
use
fa
stain
monoclon
antibodi
specif
vzv
detect
hsv
vzv
dna
naat
avail
yield
cultur
quit
variabl
depend
cultur
cell
type
use
stage
clinic
infect
yield
greatest
day
onset
specimen
type
transport
time
prefer
hour
collect
visual
cpe
sensit
cell
line
detect
hsvposit
specimen
hour
hour
hour
shell
vial
method
permit
detect
hsv
sensit
specif
hour
elvi
sensit
similar
standard
shell
vial
cultur
direct
detect
vzv
antigen
fa
smear
lesion
sensit
cultur
vesicular
fluid
although
good
cultur
inadequ
fa
test
lack
cellular
materi
direct
antigen
detect
test
hsv
variabl
sensit
specif
none
suffici
sensit
detect
asymptomat
shed
reliabl
herp
simplex
viru
varicellazost
viru
yield
csf
cultur
biopsyproven
case
hsv
enceph
hsv
pcr
perform
csf
sensit
specif
diagnost
test
choic
hsv
enceph
mening
pcr
result
posit
least
first
day
ill
even
patient
receiv
acyclovir
therapi
convers
neg
result
obtain
studi
first
csf
sampl
infant
children
singl
hsv
pcr
test
complet
exclud
hsv
enceph
hsv
pcr
also
use
clinic
specimen
type
distinguish
role
quantit
hsv
pcr
remain
unclear
result
regard
relationship
amount
hsv
csf
clinic
outcom
conflict
success
antivir
therapi
associ
declin
hsv
viral
load
csf
pcr
detect
vzv
dna
sensit
cultur
fa
particularli
scrape
older
crust
lesion
pcr
use
distinguish
vaccinetyp
versu
wildtyp
vzv
analysi
csf
pcr
detect
vzv
antibodi
csf
confirm
role
vzv
cn
syndrom
multiplex
pcr
assay
capabl
detect
vzv
herpesvirus
evalu
simplifi
diagnosi
patient
overlap
clinic
syndrom
eg
vesicular
rash
hsvspecif
igg
igm
antibodi
detect
serum
day
onset
primari
infect
igg
antibodi
indic
past
latent
current
infect
necessarili
activ
diseas
herpesvirida
latent
presenc
hsv
igg
antibodi
organ
transplant
recipi
use
risk
factor
recurr
indic
prophylact
use
acyclovir
fluctuat
hsv
igg
antibodi
titer
serolog
test
use
diagnos
recurr
hsv
infect
igm
antibodi
reliabl
indic
primari
infect
reactiv
caus
rise
igm
concentr
commerci
avail
eia
western
blot
wb
test
immunoblot
test
base
hsv
glycoprotein
g
antigen
reliabl
distinguish
typespecif
hsv
antibodi
use
typespecif
assay
provid
import
inform
epidemiolog
genit
hsv
infect
insensit
clinic
histori
recommend
propos
appropri
use
serolog
test
commerci
avail
igm
test
distinguish
infect
igg
antivzv
use
primarili
assess
suscept
infect
determin
need
vaccin
risk
diseas
expos
peopl
determin
durat
protect
vaccin
acut
vzv
infect
vzv
antibodi
appear
within
day
onset
rash
peak
week
later
greater
fourfold
rise
igg
antibodi
serum
sampl
collect
day
apart
detect
vzvspecif
igm
antibodi
singl
sampl
support
diagnosi
acut
infect
howev
serolog
diagnosi
acut
vzv
infect
confound
heterotyp
antibodi
increas
occur
one
third
patient
primari
hsv
infect
experienc
previou
vzv
infect
fa
membran
antigen
fama
consid
gold
standard
detect
vzv
antibodi
detect
neutral
antibodi
vzv
healthi
peopl
fama
latex
agglutin
correl
protect
peopl
occasion
vzv
infect
report
occur
patient
low
level
vzv
antibodi
detect
assay
eia
lower
sensit
compar
fama
latex
agglutin
assay
particularli
detect
antibodi
vaccin
newer
glycoprotein
gp
eia
appear
improv
sensit
older
eia
recogn
difficulti
serolog
test
center
diseas
control
prevent
consid
histori
receipt
valid
dose
vzv
vaccin
evid
protect
guidelin
standard
vitro
suscept
test
hsv
publish
resist
acyclovir
drug
emerg
clinic
problem
immunocompromis
patient
receiv
prolong
cours
continu
intermitt
suppress
therapi
pcr
togeth
sequenc
analysi
dna
polymeras
thymidin
kinas
gene
use
detect
mutat
confer
drug
resist
howev
approach
limit
one
interpret
presenc
mutat
associ
phenotyp
hsv
antivir
resist
signific
new
novel
mutat
requir
confirm
cytomegaloviru
cmv
detect
varieti
clinic
specimen
isol
antigen
detect
dna
probe
naat
distinguish
asymptomat
shed
urin
cervic
secret
semen
saliva
respiratori
tract
secret
activ
cmv
diseas
often
difficult
isol
cmv
tissu
good
evid
activ
infect
prefer
specimen
test
detect
diagnosi
cmv
depend
clinic
syndrom
immun
function
patient
see
chapter
enhanc
cultur
detect
cmv
variou
clinic
specimen
multipl
shell
vial
inocul
urin
specimen
tissu
bal
blood
specimen
stain
hour
observ
blood
specimen
cpe
day
isol
cmv
urin
obtain
first
week
life
diagnost
congenit
infect
situat
distinguish
whether
cmv
detect
relat
primari
infect
reactiv
reinfect
diseas
asymptomat
shed
includ
respiratori
tract
specimen
imposs
immunocompromis
patient
suspect
cmv
pneumonia
cultur
bal
specimen
compar
lung
biopsi
specimen
sensit
specif
demonstr
cmv
antigen
cell
bal
specimen
direct
fa
dfa
stain
specif
cmv
infect
sensit
reduc
histolog
examin
cell
obtain
bal
presenc
characterist
cmv
intranuclear
inclus
owl
eye
appear
suggest
diagnosi
cmv
pneumonia
detect
cmv
blood
peripher
blood
white
blood
cell
plasma
serum
whole
blood
either
cmv
antigenemia
antigen
cmv
pcr
use
diagnosi
activ
cmv
diseas
predictor
futur
cmv
diseas
transplant
recipi
immunocompromis
patient
result
quantit
semiquantit
sever
studi
support
relationship
level
cmv
blood
likelihood
activ
emerg
cmv
diseas
assay
use
preemptiv
treatment
strategi
monitor
respons
anticmv
therapi
howev
variabl
among
commerci
inhous
quantit
cmv
assay
exact
level
cmv
dna
antigenemia
use
initi
preemptiv
therapi
well
establish
diagnosi
cmv
mononucleosi
otherwis
healthi
peopl
test
cmvspecif
igm
prefer
method
howev
igm
antibodi
detect
primari
reactiv
cmv
infect
persist
month
falseposit
cmv
igm
test
result
occur
patient
acut
ebv
infect
well
patient
high
concentr
rheumatoid
factor
presenc
cmvspecif
igg
immunolog
immatur
host
immunocompromis
patient
cmv
igm
respons
acut
infect
delay
absent
igm
antibodi
cross
placenta
detect
newborn
diagnost
congenit
infect
howev
product
igm
antibodi
newborn
delay
absent
case
thu
neg
test
result
exclud
congenit
infect
major
use
cmv
igg
serolog
test
determin
suscept
infect
healthcar
childcar
worker
well
identifi
cmv
statu
blood
organ
tissu
donor
recipi
pregnant
women
cmvspecif
igg
avid
assay
may
valu
presenc
lowavid
igg
anticmv
better
predictor
recent
infect
igm
alon
thu
increas
likelihood
cmv
transmiss
fetu
howev
substanti
variabl
perform
differ
cmv
avid
assay
preclud
clear
guidanc
use
interpret
addit
test
pcr
viru
isol
amniot
fluid
may
requir
confirm
infect
fetu
standard
vitro
cmv
antivir
suscept
test
establish
despit
util
test
immunocompromis
patient
resist
correl
clinic
failur
phenotyp
assay
limit
long
turnaround
time
expertis
requir
perform
genotyp
assay
detect
common
mutat
cmv
phosphotransferas
gene
dna
polymeras
gene
confer
antivir
resist
assay
avail
wide
epsteinbarr
viru
patient
suspect
ebv
infecti
mononucleosi
im
heterophil
antibodi
remain
serolog
test
choic
igm
antibodi
detect
easili
rapidli
use
simpl
spot
agglutin
assay
often
refer
monospot
immunochromatograph
assay
heterophil
antibodi
develop
approxim
adolesc
adult
ebv
im
within
week
onset
ill
respons
delay
peopl
repeat
test
may
requir
result
heterophil
test
neg
ebv
infect
children
year
age
heterophil
antibodi
usual
disappear
within
month
persist
year
acut
ill
patient
persist
interpret
indic
recurr
chronic
im
case
heterophileneg
im
schoolag
children
caus
cmv
ebv
proven
ebvspecif
serolog
find
case
ebv
serolog
test
indic
diagnosi
ebv
infect
strongli
suspect
heterophil
test
result
neg
indic
activ
infect
isol
saliva
healthi
adult
well
ill
peopl
thu
question
valu
test
isol
rare
pbmc
healthi
asymptomat
peopl
compar
peopl
activ
infect
find
suggest
pbmc
cultur
may
diagnost
valu
specif
primer
pcr
amplif
develop
amplifi
dna
human
herpesvirus
includ
multiplex
assay
human
herpesviru
test
avail
research
set
pcr
use
detect
dna
pbmc
tissu
use
plasma
serum
pcr
valu
identifi
activ
infect
serolog
assay
detect
igg
igm
although
serolog
test
use
seropreval
studi
role
test
diagnos
manag
infect
establish
numer
virus
includ
rsv
influenza
virus
b
human
parainfluenza
virus
type
adenovirus
subtyp
e
rhinovirus
human
coronavirus
sever
acut
respiratori
syndrom
sar
coronaviru
human
metapneumoviru
hmpv
middl
east
respiratori
coronaviru
mer
cov
infect
respiratori
tract
caus
clinic
indistinguish
sign
symptom
increas
develop
naat
detect
respiratori
virus
whether
individu
multiplex
pcr
assay
significantli
simplifi
improv
diagnosi
viral
respiratori
tract
infect
naat
appli
np
wash
aspir
swab
well
bal
endotrach
tube
ett
aspir
superior
sensit
cultur
antigen
detect
earli
sampl
collect
within
first
day
symptom
onset
improv
sensit
result
naat
avail
within
hour
thu
substanti
shorten
turnaround
time
compar
cultur
mean
day
naat
avail
laboratori
may
continu
use
cultur
antigen
detect
test
sensit
antigen
detect
techniqu
rsv
influenza
virus
eia
microtit
plate
kit
membran
filter
eia
dfa
rang
specif
membran
filter
eia
rsv
detect
offer
advantag
provid
result
within
minut
sever
rapid
antigen
detect
kit
includ
pointofcar
test
avail
detect
influenza
influenza
b
togeth
without
distinguish
influenza
b
evalu
rapid
test
detect
season
influenza
viru
well
pandem
viru
indic
rel
poor
sensit
affect
circul
strain
specimen
type
high
specif
test
evalu
fulli
detect
avian
influenza
goodqual
respiratori
specimen
wellpreserv
epitheli
cell
use
dfa
stain
use
monoclon
antibodi
sensit
specif
antigen
detect
assay
detect
multipl
respiratori
virus
simultan
numer
studi
confirm
superior
naat
detect
respiratori
virus
test
capabl
detect
mutat
within
influenza
strain
confer
resist
neuraminidas
inhibitor
use
serolog
test
diagnosi
acut
respiratori
viru
infect
gener
littl
clinic
valu
epidemiolog
purpos
test
routin
avail
play
role
determin
immun
respons
vaccin
eg
influenza
viru
routin
diagnosi
infect
hepat
virus
base
serolog
test
serum
plasma
use
separ
blood
within
hour
collect
diagnosi
acut
hav
infect
made
demonstr
igm
antihav
immun
hav
follow
natur
infect
immun
determin
measur
hepat
igg
total
igg
igm
antihav
current
role
exist
revers
transcriptas
rt
pcr
measur
hav
rna
routin
diagnosi
assist
character
strain
outbreak
investig
acut
chronic
hbv
infect
hbsag
antihepat
b
core
antibodi
hbcab
usual
present
igm
antihbc
gener
ifa
test
consid
gold
standard
although
eia
immunoblot
assay
use
ifa
test
uniform
perform
characterist
wherea
eia
vari
wide
varieti
antigen
prepar
use
differ
kit
use
diagnost
test
igm
antiebv
viral
capsid
antigen
vca
appear
within
week
onset
symptom
disappear
within
month
sensit
specif
falseposit
result
reflect
presenc
rheumatoid
factor
herpesviru
infect
antinuclear
factor
eia
test
system
falseneg
result
occur
sampl
collect
late
cours
ill
igg
antivca
elev
symptom
ill
persist
life
thu
reliabl
marker
ebv
seroposit
igg
antiepsteinbarr
nuclear
antigen
ebna
appear
late
gener
week
persist
life
sever
month
recov
im
patient
expect
igg
antibodi
vca
ebna
low
absent
vca
igm
antibodi
ea
antibodi
see
fig
direct
test
ebv
cultiv
cord
blood
leukocyt
direct
detect
immunofluoresc
stain
detect
dna
perform
laboratori
ebv
isol
oropharyng
wash
circul
lymphocyt
patient
im
pcr
detect
ebv
dna
csf
patient
hiv
infect
strongli
associ
primari
cn
lymphoma
follow
organ
marrow
transplant
use
quantit
ebv
pcr
use
blood
specimen
help
predict
develop
posttranspl
lymphoprolif
diseas
rel
merit
test
whole
blood
leukocyt
plasma
serum
unclear
elev
level
ebv
dna
peripher
blood
indic
decreas
immunosuppress
therapi
consid
therapi
monoclon
antibodi
ebvspecif
cytotox
lymphocyt
rare
ebv
infect
associ
acut
fulmin
diseas
eg
xlink
lymphoprolif
syndrom
virusassoci
hemophagocyt
syndrom
persist
hightit
ebv
antibodi
except
ebna
characterist
absent
diagnosi
depend
detect
viru
genom
human
herpesviru
primari
infect
human
herpesviru
occur
children
age
year
routin
laboratori
test
usual
perform
detect
antibodi
primari
infect
gener
appear
day
onset
fever
follow
serolog
criteria
consid
diagnost
primari
infect
antibodi
seroconvers
acut
convalesc
phase
serum
plasma
specimen
collect
week
apart
detect
lowavid
igg
antibodi
posit
serum
igm
absenc
igg
antibodi
greater
fourfold
rise
igg
antibodi
ifa
anticomplementari
immunofluoresc
assay
current
commerci
assay
igg
distinguish
variant
b
crossreact
cmv
antibodi
avid
test
use
differenti
primari
infect
igm
alon
reliabl
indic
acut
recent
infect
igm
found
reactiv
reinfect
approxim
adult
detect
igm
time
igm
may
detect
cultureposit
children
acut
primari
infect
viru
isol
cultur
peripher
blood
mononuclear
cell
pbmc
infant
recoveri
dna
detect
pcr
acut
ill
recoveri
monoclon
antibodi
avail
direct
detect
antigen
use
confirm
cell
cultur
cpe
immunohistochem
stain
tissu
immunocompromis
patient
infect
associ
substanti
morbid
mortal
rate
proof
causat
difficult
specif
antibodi
absent
demonstr
viral
dna
pbmc
repres
latent
infect
although
pcr
detect
dna
serum
plasma
low
sensit
better
marker
activ
infect
pcr
result
neg
serum
plasma
healthi
adult
posit
patient
exanthem
subitum
bone
marrow
transplant
recipi
hivinfect
patient
human
herpesviru
serolog
test
avail
wide
degre
crossreact
antibodi
result
crossreact
epitop
virus
respons
distinguish
antibodi
avid
test
signific
rise
antibodi
stabl
absent
antibodi
may
hdv
superinfect
patient
chronic
infect
hbv
antihdv
gener
persist
indefinit
infect
becom
chronic
case
measur
hdv
rna
rtpcr
remain
research
test
igg
igm
antihev
measur
use
research
commerci
assay
use
differ
antigen
assay
show
signific
variabl
sensit
specif
igg
antihev
posit
patient
week
onset
diseas
becom
undetect
month
igg
antihev
typic
declin
infect
area
hev
endem
rtpcr
prove
use
confirmatori
test
multitud
virus
caus
acut
gastroenter
case
laboratori
diagnosi
requir
indic
except
perhap
infect
control
purpos
institut
outbreak
public
health
reason
stool
sampl
place
clean
steril
contain
without
vtm
preserv
detect
enter
virus
collect
within
first
hour
ill
rectal
swab
may
contain
suffici
viru
em
detect
stool
specimen
stabl
week
although
freez
permit
prolong
storag
em
detect
reduc
repeat
freez
thaw
destroy
morpholog
featur
viral
structur
none
enter
virus
cultiv
readili
convent
cell
cultur
system
detect
em
commerci
eia
latex
agglutin
membranebas
test
sensit
specif
avail
detect
rotavirus
norovirus
enter
adenovirus
astrovirus
pcrbase
assay
includ
multiplex
assay
virus
avail
commerci
method
choic
diagnos
enter
virus
serolog
test
enter
virus
clinic
role
except
outbreak
investig
enterovirus
gener
stabl
surviv
environ
week
rapid
transport
clinic
specimen
laboratori
critic
enteroviru
viabil
decreas
slowli
day
week
room
temperatur
preserv
decad
appropri
specimen
includ
follow
csf
serum
whole
blood
pericardi
fluid
tissu
biopsi
sampl
eg
myocardium
urin
stool
rectal
nasal
throat
swab
although
mani
enterovirus
grown
cell
cultur
serotyp
eg
coxsackieviru
group
fail
grow
standard
cell
cultur
isol
enterovirus
requir
day
viru
isol
frequent
stool
throat
swab
csf
serum
peripher
leukocyt
lack
common
antigen
among
enterovirus
immunoassay
direct
detect
avail
em
use
diagnosi
low
quantiti
viru
clinic
sampl
rtpcr
use
test
csf
cardiac
tissu
pericardi
fluid
well
serum
significantli
improv
speed
detect
enterovirus
report
sensit
specif
comparison
cultur
sensit
detect
urin
sampl
poor
probabl
nonspecif
inhibitor
pcr
respiratori
specimen
crossamplif
rhinovirus
occur
clinic
detect
enterovirus
stool
respiratori
specimen
must
interpret
cautious
asymptomat
shed
wild
enteroviru
gastrointestin
tract
occur
week
month
addit
oral
polio
vaccin
viru
shed
stool
less
commonli
throat
young
vaccin
children
detect
viru
csf
genitourinari
tract
tissu
blood
proof
caus
role
measur
antibodi
titer
enterovirus
limit
diagnost
valu
separ
neutral
assay
must
perform
enteroviru
subtyp
laboratori
diagnosi
measl
mump
rubella
mmr
virus
made
viru
isol
detect
antigen
use
rtpcr
serolog
test
suitabl
sampl
isol
detect
viral
indic
acut
hbv
infect
also
detect
flare
inflamm
chronic
carrier
definit
person
persist
posit
hbsag
month
consid
chronic
infect
isol
antihbc
posit
occur
acut
infect
loss
detect
hbsag
emerg
detect
hbsab
core
window
late
chronic
infect
hbsag
level
fallen
less
detect
level
coinfect
hcv
hiv
suppress
hbsag
product
infect
mutant
hbv
falseposit
result
role
quantit
hbsag
assay
evalu
monitor
patient
chronic
hbv
infect
presenc
hbv
e
antigen
hbeag
absenc
antihb
marker
greater
infect
correl
increas
risk
progress
chronic
hepat
cirrhosi
hepatocellular
carcinoma
presenc
antihb
indic
like
recoveri
presenc
hbsab
level
iuml
consid
protect
acut
infect
hbsab
level
declin
less
iuml
year
mani
vaccin
respond
peopl
remain
protect
acut
infect
like
result
immun
memori
presenc
hbsab
alon
reflect
previou
immun
wherea
presenc
hbsab
togeth
hbcab
reflect
recoveri
previou
natur
infect
although
hbsag
hbsab
believ
mutual
exclus
mani
one
third
carrier
hbsag
also
detect
hbsab
mechan
uncertain
may
relat
coinfect
differ
subtyp
thu
current
recommend
peopl
hbsab
posit
test
hbsag
least
diagnosi
hcv
infect
secondand
thirdgener
eia
supplementari
recombin
immunoblot
assay
use
recombin
structur
protein
wide
avail
seroconvers
occur
week
follow
acut
infect
sensit
except
immunocompromis
peopl
specif
supplementari
recombin
immunoblot
assay
test
hcv
antibodi
antihcv
frequent
neg
onset
jaundic
presenc
hcv
antibodi
indic
activ
infect
approxim
patient
remain
patient
like
clear
viru
spontan
result
antivir
treatment
use
hcv
rna
assay
help
distinguish
possibl
assay
avail
current
detect
igm
antihcv
util
measur
hcv
antigen
serum
plasma
establish
evalu
potenti
altern
hcv
rna
monitor
patient
therapi
molecular
assay
detect
quantif
hbv
hcv
viral
nucleic
acid
serum
use
determin
prognosi
select
candid
therapi
monitor
respons
therapi
lower
baselin
concentr
indic
better
prognosi
greater
likelihood
respons
treatment
patient
respond
antivir
treatment
demonstr
signific
drop
hbv
dna
hcv
rna
wherea
nonrespond
molecular
assay
also
avail
hbv
hcv
genotyp
antivir
resist
test
naat
detect
hcv
rna
serum
week
exposur
use
part
blood
organ
tissu
donor
screen
patient
indetermin
hcv
antibodi
result
recombin
immunoblot
assay
result
inconclus
clinic
situat
test
hepat
b
c
group
categori
acut
hepat
chronic
hepat
immun
statu
previou
exposur
suspect
acut
hepat
initi
test
igm
antihav
hbsag
antihcv
perform
result
neg
igm
antihbc
test
repeat
test
antihcv
recommend
week
chronic
hepat
suspect
test
includ
hbsag
antihcv
clinician
also
may
test
antihbc
patient
screen
immun
previou
infect
follow
test
total
igg
antihav
hbsab
hbcab
depend
whether
one
tri
distinguish
vaccin
respons
evid
previou
infect
antihcv
marker
previou
infect
immun
serolog
test
avail
hepat
delta
agent
viru
hdv
hepat
e
viru
hev
none
approv
food
drug
administr
fda
infect
hdv
occur
sole
conjunct
hbv
infect
test
antihdv
perform
patient
acut
chronic
infect
hbv
coinfect
hbv
hdv
antihdv
disappear
within
month
follow
recoveri
acut
infect
howev
part
iv
laboratori
diagnosi
therapi
infecti
diseas
collect
none
assay
approv
use
peopl
infect
group
molecular
assay
avail
genotyp
detect
antiretrovir
resist
mutat
resist
test
recommend
initi
therapi
treatment
fail
phenotyp
assay
also
perform
purpos
mainstay
diagnosi
hiv
remain
hivspecif
serolog
test
use
screen
eia
less
commonli
particl
agglutin
assay
follow
confirmatori
test
use
wb
assay
serum
plasma
accept
specimen
test
system
dri
blood
spot
urin
saliva
also
avail
thirdand
fourthgener
eia
kit
use
purifi
viru
antigen
cell
lysat
recombin
viral
protein
synthet
peptid
antigen
detect
group
assay
increas
sensit
specif
fewer
indetermin
result
current
avail
assay
detect
igg
igm
assay
fourthgener
screen
test
detect
antibodi
antigen
time
reduc
seroconvers
window
period
approxim
day
detun
also
known
sensit
less
sensit
eia
capabl
measur
affin
hiv
antibodi
use
distinguish
recent
past
distant
hiv
infect
estim
incid
rate
wb
princip
confirmatori
test
hiv
serolog
statu
even
though
sensit
seroconvers
panel
inferior
thirdand
fourthgener
screen
test
separ
wb
test
must
use
confirm
wb
measur
antibodi
respons
protein
p
glycoprotein
gp
howev
test
prone
give
high
rate
indetermin
result
detect
crossreact
antibodi
nonspecif
reaction
criterion
confirm
infect
use
wb
presenc
antibodi
follow
antibodi
respons
protein
repres
neg
test
result
wherea
presenc
antibodi
requir
posit
interpret
indetermin
result
circumst
repeat
test
next
month
recommend
wb
result
remain
indetermin
patient
consid
infect
hiv
lowrisk
popul
peopl
posit
screen
eia
test
result
indetermin
wb
result
rare
ever
infect
hiv
followup
serolog
test
rapid
multispot
assay
develop
altern
wb
distinguish
good
sensit
specif
ifa
test
detect
igg
igm
quit
sensit
specif
use
altern
wb
confirmatori
test
line
immunoassay
use
confirm
includ
group
singl
test
rapid
pointofcar
test
screen
confirm
requir
minim
laboratori
equip
develop
yield
result
minut
sensit
specif
compar
thirdgener
eiabas
test
confirmatori
assay
differ
laboratori
diagnost
strategi
need
common
situat
hiv
infect
consid
adult
older
child
suspect
hiv
infect
infant
suspect
vertic
acquir
hiv
infect
someon
acut
infect
seroconvers
may
develop
exposur
hivinfect
person
one
refer
recent
guidelin
center
diseas
control
prevent
uptod
recommend
screen
confirm
hiv
infect
notabl
chang
recommend
replac
wb
discriminatori
assay
antigen
test
naat
sensit
antigen
test
vari
accord
clinic
diseas
statu
asymptomat
infect
peopl
patient
aidsrel
complex
patient
aid
confirm
vertic
transmiss
hiv
use
eia
wb
confound
presenc
matern
antibodi
month
age
antibodi
test
use
diagnosi
neonat
infect
current
recommend
virolog
assay
naat
hiv
rna
hiv
dna
directli
detect
hiv
must
use
diagnos
hiv
infect
infant
younger
month
age
hiv
cultur
consid
gold
standard
antigen
assay
use
situat
base
complex
cost
cultur
lack
sensit
antigen
assay
antigen
includ
whole
blood
particularli
pbmc
isol
measl
serum
buccal
swab
throat
np
secret
urin
appropri
clinic
circumst
csf
brain
skin
biopsi
sampl
labil
virus
rapid
transport
laboratori
import
specimen
best
kept
process
frozen
delay
hour
anticip
isol
viru
blood
greatest
day
rash
onset
declin
rapidli
within
day
thereaft
conjunctiv
np
sampl
isol
measl
viru
collect
day
day
onset
rash
throat
swab
rubella
viru
isol
usual
posit
collect
day
rash
onset
rapidli
becom
neg
within
day
mump
viru
isol
saliva
day
day
onset
parot
virus
cultiv
convent
cell
line
isol
requir
day
measl
mump
viru
week
rubella
viru
shell
vial
method
measl
viru
sensit
day
day
sensit
dfa
stain
np
swab
specimen
measl
viru
antigen
compar
cultur
throat
swab
urin
specimen
shell
vial
cultur
detect
mump
viru
sensit
specif
compar
tradit
cultur
molecular
diagnosi
use
virusspecif
rtpcr
use
detect
virus
use
genotyp
help
differenti
wildtyp
vaccineviru
strain
time
serum
specimen
collect
critic
mani
patient
igm
antibodi
time
rash
onset
suspect
measl
viru
infect
serum
collect
within
day
rash
onset
rubella
viru
infect
patient
igm
posit
day
rash
onset
although
tradit
mmr
serolog
test
hemagglutin
inhibit
igg
antibodi
sever
ifa
eia
igg
igm
kit
avail
commerci
declin
preval
viral
diseas
posit
predict
valu
igm
test
low
presenc
rheumatoid
factor
lead
falseposit
igm
result
reexposur
previous
vaccin
person
someon
histori
natur
infect
result
secondari
igg
igm
respons
mump
igm
antibodi
persist
month
acut
ill
patient
im
parvoviru
infect
measl
viru
cmv
infect
crossreact
igm
antirubella
antibodi
similarli
infect
parvoviru
rubella
viru
result
crossreact
igm
antimeasl
pregnant
women
igm
antirubella
confirm
second
igm
assay
detect
signific
rise
igg
antibodi
avid
assay
igg
antibodi
measl
rubella
virus
avail
measur
virusspecif
igg
antibodi
use
determin
immun
statu
mump
viru
crossreact
paramyxovirus
occur
rubella
viru
igg
level
iuml
thought
repres
immun
case
major
diagnost
test
hiv
serolog
eia
ifa
wb
hiv
antibodi
eia
antigen
cultur
naat
detect
rna
plasma
provir
dna
whole
blood
pbmc
cultur
hiv
longer
use
routin
diagnosi
naat
use
diagnosi
infect
neonat
excel
sensit
specif
screen
test
rna
part
routin
blood
organ
tissu
donor
screen
program
sinc
test
also
use
measur
specimen
type
includ
csf
cervic
secret
semin
plasma
semen
serum
use
naat
peopl
known
hiv
seroposit
yield
falseposit
result
major
use
quantit
viral
load
assay
monitor
patient
respons
antiretrovir
therapi
intraassay
biolog
variabl
rna
level
greater
threefold
chang
consid
clinic
relev
differ
molecular
assay
also
produc
signific
differ
viral
load
thu
baselin
valu
repeat
laboratori
test
chang
assay
anoth
assay
yield
lower
level
patient
serum
use
instead
plasma
blood
collect
acidcitratedextros
anticoagul
rather
edta
current
avail
commerci
assay
vari
specimen
volum
requir
rang
ml
lower
limit
detect
dynam
rang
time
result
regardless
assay
format
plasma
must
separ
blood
cell
within
hour
recommend
specimen
laboratori
test
virus
list
tabl
virus
test
perform
highli
special
research
refer
laboratori
major
virus
infect
fetus
newborn
infant
extend
beyond
tradit
torch
toxoplasma
rubella
viru
cmv
hsv
agent
includ
cmv
vzv
hsv
rubella
parvoviru
hbv
hcv
hev
enterovirus
hiv
neg
matern
neonat
serolog
test
result
virus
gener
exclud
fetal
infect
detect
viru
cultur
antigen
detect
naat
requir
correct
diagnosi
made
cord
blood
yield
falseposit
falseneg
result
reli
diagnosi
congenit
cmv
infect
best
diagnos
isol
cmv
urin
neonat
within
first
week
life
beyond
week
age
isol
cmv
urin
distinguish
congenit
perinat
postnat
infect
igm
anticmv
newborn
posit
congenit
infect
neonat
test
yield
falseposit
result
congenit
vzv
infect
diagnos
serolog
test
perinat
postnat
infect
vzv
well
infect
hsv
enterovirus
usual
diagnos
convent
antigen
detect
cultur
techniqu
although
naat
test
replac
test
center
serolog
diagnosi
neonat
hsv
infect
inappropri
respons
may
detect
week
infect
demonstr
rubella
igm
neonat
featur
consist
congenit
rubella
confirm
diagnosi
viru
isol
requir
week
parvoviru
infect
pregnanc
diagnos
mother
serolog
test
detect
igm
rise
igg
antibodi
concentr
diagnost
wherea
stabl
igg
titer
reflect
past
infect
parvoviru
infect
fetu
hydrop
confirm
use
naat
viral
dna
fetal
blood
amniot
fluid
cell
chlamydiacea
chlamydia
trachomati
chlamydophila
pneumonia
chlamydophila
psittaci
caus
diseas
human
psittacosi
rare
children
confirm
serolog
cultur
noncultur
method
avail
detect
c
trachomati
cultur
previous
consid
gold
standard
specif
excel
sensit
optim
techniqu
use
howev
genit
specimen
sensit
approxim
compar
naat
becom
test
choic
routin
test
test
firstvoid
urin
men
women
commerci
avail
naat
excel
sensit
specif
result
high
posit
predict
valu
noncultur
method
eia
ifa
test
nucleic
acid
probe
test
littl
role
routin
test
c
trachomati
inferior
perfom
pointofcar
test
poor
sensit
specif
recommend
optim
specimen
type
collect
method
transport
requir
vari
depend
test
method
use
purpos
test
screen
vs
diagnosi
age
sex
patient
test
gener
lower
sensit
technic
requir
prolong
turnaround
time
cultur
perform
routin
detect
urogenit
c
trachomati
infect
cultur
replac
naat
test
choic
male
patient
either
urethr
swab
insert
cm
firstcatch
urin
sampl
prefer
specimen
women
swab
cervic
os
insert
cm
vagin
swab
includ
selfcollect
vulvovagin
swab
firstcatch
urin
sampl
accept
specimen
naat
use
adult
sexual
assault
victim
implic
assess
although
naat
evalu
sexual
abus
test
infant
known
perinat
hiv
exposur
recommend
age
day
month
month
age
diagnosi
hiv
infect
children
nonperinat
exposur
children
perinat
exposur
month
age
follow
recommend
test
adult
suspect
hiv
infect
base
primarili
use
hiv
antibodi
test
person
known
hiv
exposur
antibodi
viru
usual
detect
within
week
infect
base
thirdgener
screen
assay
hiv
antibodi
detect
infect
patient
within
week
infect
remain
patient
within
month
virtual
infect
immunocompet
peopl
seroposit
month
exposur
mononucleosislik
syndrom
develop
patient
week
infect
antigen
appear
transient
period
arbovirus
laboratori
test
gener
perform
arboviru
infect
arbovirus
caus
cn
diseas
brief
low
level
viremia
occur
clear
patient
seek
medic
attent
thu
blood
specimen
viru
isol
naat
rare
yield
posit
result
unless
collect
neuroinvas
phase
ill
arboviru
infect
includ
dengu
yellow
fever
sandfli
fever
venezuelan
enceph
colorado
tick
fever
rel
high
level
viremia
occur
persist
day
week
make
viru
isol
naat
blood
specimen
possibl
viru
isol
neurotrop
virus
brain
tissu
csf
occasion
success
acut
phase
infect
naat
sensit
case
arboviru
infect
diagnosi
establish
igg
seroconvers
detect
specif
igm
antibodi
collect
pair
acut
collect
first
week
ill
convalesc
collect
week
later
sera
recommend
singl
sampl
may
suffici
diagnosi
specif
igm
test
avail
eg
eastern
equin
encephalomyel
viru
western
equin
encephalomyel
viru
california
la
cross
viru
st
loui
enceph
viru
west
nile
viru
dengu
viru
howev
case
eg
west
nile
viru
virusspecif
igm
detect
serum
year
follow
infect
cn
diseas
serum
csf
specimen
test
sensit
test
approach
day
ill
tradit
assay
cf
hemagglutin
inhibit
test
larg
replac
fa
eia
serolog
crossreact
occur
among
antigen
relat
virus
eg
st
loui
enceph
west
nile
japanes
enceph
dengu
powassan
flavivirus
plaqu
reduct
neutral
test
remain
specif
test
serolog
diagnosi
arboviru
infect
neutral
antibodi
best
indic
protect
immun
parvoviru
cultiv
routin
cell
cultur
thu
serolog
test
rise
igg
titer
presenc
igm
antibodi
mainstay
diagnosi
igm
antibodi
detect
serum
approxim
day
infect
rash
joint
symptom
begin
persist
sever
month
sensit
igm
antiparvoviru
exce
first
month
onset
symptom
igg
antibodi
appear
sever
day
igm
gener
persist
year
current
igg
assay
sensit
igg
indic
past
infect
reexposur
parvoviru
lead
rise
igg
antibodi
level
igg
avid
assay
help
distinguish
primari
secondari
infect
naat
detect
viral
dna
serum
specimen
type
may
requir
diagnosi
immunocompromis
patient
parvovirusassoci
aplast
crisi
chronic
infect
congenit
infect
diagnos
pcr
test
serum
pcr
also
use
detect
parvoviru
dna
bone
marrow
aspir
cord
blood
sampl
amniot
fluid
cell
biopsi
specimen
placenta
fetal
tissu
case
fetal
hydrop
howev
parvoviru
dna
may
detect
serum
month
acut
infect
year
tissu
thu
diagnosi
acut
chronic
parvoviru
infect
requir
serolog
test
quantit
pcr
part
iv
laboratori
diagnosi
therapi
infecti
diseas
speci
given
poor
sensit
cf
test
use
diagnosi
isol
c
pneumonia
difficult
stabil
c
pneumonia
clinic
specimen
well
studi
although
studi
report
organ
remain
viabl
hour
throat
swab
sputum
np
bal
respiratori
tract
specimen
place
transport
media
use
variabl
success
detect
organ
respiratori
secret
prove
causal
asymptomat
infect
occur
children
persist
shed
occur
month
acut
diseas
adult
molecular
diagnosi
noncommerci
convent
realtim
pcr
test
evalu
sensit
appear
good
cultur
specif
difficult
determin
given
lack
gold
standard
comparison
rapid
accur
diagnosi
mycoplasma
pneumonia
infect
problemat
lack
wellstandard
test
cultur
wide
accept
method
test
respiratori
tract
secret
avail
limit
special
broth
agar
media
requir
yield
rel
low
optim
isol
specimen
bal
tracheobronchi
secret
sputum
np
aspir
swab
tissu
blood
csf
joint
fluid
inocul
appropri
media
eg
bedsid
media
accept
isol
pcr
assay
specimen
refriger
process
within
hour
pneumonia
rel
slow
grow
cultur
maintain
week
result
report
neg
shed
pneumonia
persist
sever
week
onset
ill
particularli
children
therebi
confound
interpret
posit
cultur
result
direct
antigen
test
eia
dfa
immunoblot
respiratori
tract
secret
sputum
np
aspir
perform
well
research
set
sensit
test
avail
wide
crossreact
commens
mycoplasma
occur
persist
shed
detect
antigen
asymptomat
peopl
confound
interpret
posit
result
present
test
neither
recommend
use
routin
clinic
set
convent
realtim
pcr
test
detect
pneumonia
respiratori
secret
wide
evalu
pcr
test
consist
sensit
cultur
antigen
detect
despit
rel
high
sensit
studi
suggest
pcr
use
alon
make
diagnosi
acut
recent
infect
result
must
use
conjunct
result
serolog
test
perform
csf
pcr
use
diagnosi
pneumoniaeassoci
meningoenceph
serolog
diagnosi
measur
antim
pneumonia
igg
igm
iga
antibodi
perform
commerci
avail
eia
fa
latex
agglutin
kit
test
sensit
specif
cf
assay
replac
cf
mani
diagnost
laboratori
use
limit
mani
children
igm
neg
time
present
time
seroconvers
week
children
adolesc
young
adult
singl
posit
igm
result
consid
diagnost
although
falseposit
result
occur
combin
serolog
result
togeth
cultur
pcr
may
provid
reliabl
approach
diagnosi
cold
agglutinin
antibodi
titer
simpl
perform
wide
avail
peopl
infect
pneumonia
develop
cold
agglutinin
antibodi
test
lack
sensit
specif
use
serolog
diagnosi
pneumonia
infect
genit
mycoplasma
laboratori
diagnosi
ureaplasma
urealyticum
mycoplasma
homini
infect
achiev
isol
organ
use
special
broth
agar
media
organ
grow
rapidli
cultur
result
posit
within
day
pcr
includ
multiplex
assay
use
detect
u
urealyticum
homini
clinic
specimen
mycoplasma
genitalium
grow
slowli
cultur
may
children
medic
legal
implic
evalu
cultur
remain
recommend
method
urethr
specimen
boy
extragenit
specimen
pharynx
conjunctiva
rectum
boy
girl
naat
use
vagin
specimen
urin
specimen
girl
howev
none
commerci
avail
naat
fda
approv
use
test
specimen
extragenit
site
yield
cultur
relat
directli
qualiti
specimen
transport
storag
condit
test
isol
c
trachomati
cultur
urethr
specimen
collect
prepubert
boy
low
recommend
howev
urethr
discharg
present
meatal
specimen
collect
low
yield
pharyng
specimen
isol
c
trachomati
recommend
children
either
sex
cultur
dacron
cottonor
rayontip
swab
aluminum
plastic
shaft
recommend
swab
wooden
shaft
calcium
algin
tip
inhibit
growth
organ
swab
place
immedi
chlamydi
transport
media
contain
sucros
phosphat
sucros
phosphat
glutam
supplement
bovin
serum
antimicrobi
agent
transport
laboratori
within
hour
freez
result
loss
viabil
freez
avoid
collect
endocerv
urethr
swab
specimen
naat
follow
instruct
manufactur
swab
specimen
naat
stabl
room
temperatur
day
urin
specimen
naat
stabl
hour
room
temperatur
refriger
day
store
lower
month
process
sever
fdaapprov
naat
avail
simultan
detect
c
trachomati
neisseria
gonorrhoea
base
pcr
transcriptionmedi
amplif
strand
displac
amplif
excel
sensit
specif
perform
hour
howev
perform
equal
well
specimen
type
genet
variant
c
trachomati
identifi
sweden
undetect
pcr
find
rais
import
continu
assess
differ
naat
ensur
optim
perform
serolog
test
c
trachomati
genit
tract
infect
use
diagnosi
individu
patient
antibodi
c
trachomati
persist
life
infant
detect
antic
trachomati
igm
antibodi
use
microimmunofluoresc
mif
test
diagnost
test
choic
chlamydi
pneumonia
matern
igg
antibodi
persist
infant
month
mif
test
sensit
serolog
test
one
detect
speciesand
serovarspecif
respons
eia
detect
igm
antibodi
infant
variabl
perform
compar
mif
test
specif
c
trachomati
interpret
singl
igg
antibodi
test
result
difficult
peopl
antibodi
c
pneumonia
cf
test
use
wide
diagnosi
psittacosi
lymphogranuloma
venereum
valu
diagnos
genit
tract
neonat
chlamydi
infect
antimicrobi
suscept
test
chlamydia
speci
standard
vitro
result
necessarili
correl
clinic
respons
treatment
therefor
role
exist
routin
suscept
test
clinic
manag
test
gener
restrict
research
laboratori
accur
laboratori
confirm
acut
infect
c
pneumonia
difficult
often
base
serolog
test
despit
high
seropreval
organ
adult
mif
test
appear
reliabl
serolog
test
diagnosi
acut
infect
follow
criteria
posit
test
use
greater
fourfold
rise
titer
igm
titer
igg
titer
igg
titer
consid
evid
previou
necessarili
recent
infect
howev
mif
test
limit
lack
standard
avail
highqual
reagent
inabl
distinguish
past
persist
infect
comparison
eia
use
speciesspecif
assay
mif
shown
good
sensit
specif
children
respiratori
tract
diseas
control
children
eia
detect
antibodi
lipopolysaccharid
test
detect
antibodi
chlamydia
